Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Tables)

6 Months Ended

Jan. 31, 2022

Three months ended January 31, 2022	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues	$	23,674		$	10,372			—			—		$	34,046

Operating costs and expenses:
Cost of revenues		12,586			5,252			—			—			17,838
Research and development		89			711			20			—			820
Selling, general and administrative		6,811			3,039			—			4,616			14,466
Legal fee expense		148			—			—			2,697			2,845
Total operating costs and expenses		19,634			9,002			20			7,313			35,969

Operating income (loss)		4,040			1,370			(20	)		(7,313	)		(1,923	)

Other income (expense):
Interest, net		(3	)		9			—			62			68
Other		5			3			—			(358	)		(350	)
Foreign exchange loss		—			(450	)		—			—			(450	)
Net income (loss)	$	4,042		$	932		$	(20	)	$	(7,609	)	$	(2,655	)

Depreciation and amortization included above	$	438			190			—			77			705

Share-based compensation included in above:
Selling, general and administrative		16			1			—			650			667
Cost of revenues		12			—			—			—			12
Total	$	28			1			—			650			679

Capital expenditures	$	283			730			—			201			1,214

Three months ended January 31, 2021	Clinical Services			Products		Therapeutics			Other			Consolidated
Revenues – Services and Products	$	23,988		$	7,478		—			—		$	31,466

Operating costs and expenses:
Cost of revenues		11,708			3,937		—			—			15,645
Research and development		160			633	$	13			—			806
Selling, general and administrative		6,425			2,593		16		$	1,979			11,013
Legal and related expenses		71			1		—			2,220			2,292
Total operating costs and expenses		18,364			7,164		29			4,199			29,756

Operating income (loss)		5,624			314		(29	)		(4,199	)		1,710

Other income (expense):
Interest		(4	)		8		—			(53	)		(49	)
Other		14			2		—			—			16
Foreign exchange gain		—			625		—			—			625
Net income (loss)	$	5,634		$	949	$	(29	)	$	(4,252	)	$	2,302

Depreciation and amortization included above	$	381		$	188	$	—		$	66		$	635

Share-based compensation included in above:
Selling, general and administrative		10			16		—			136			162
Cost of revenues		14			—		—			—			14
Total	$	24		$	16	$	—		$	136		$	176

Capital expenditures	$	341		$	154	$	—		$	11		$	506

Six months ended January 31, 2022	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues – Services and Products	$	43,415		$	17,150			—			—		$	60,565

Operating costs and expenses:
Cost of revenues		23,789			9,322			—			—			33,111
Research and development		96			1,443		$	25			—			1,564
Selling, general and administrative		12,812			6,134			—		$	6,572			25,518
Legal and related expenses		205			13			—			3,909			4,127
Total operating costs and expenses		36,902			16,912			25			10,481			64,320

Operating income (loss)		6,513			238			(25	)		(10,481	)		(3,755	)

Other income (expense):
Interest		(5	)		18			—			94			107
Other		54			5			—			(554	)		(495	)
Foreign exchange (loss)					(831	)		—			—			(831	)
Net income (loss)	$	6,562		$	(570	)	$	(25	)	$	(10,941	)	$	(4,974	)

Depreciation and amortization included above	$	856		$	402		$	—		$	148		$	1,406

Share-based compensation included in above:
Selling, general and administrative		36			1			—			842			879
Cost of revenues		16			—			—			—			16
Total	$	52		$	1		$	—		$	842		$	895

Capital expenditures	$	593		$	1,216		$	—		$	438		$	2,247

Six months ended January 31, 2021	Clinical Services			Products		Therapeutics			Other			Consolidated
Revenues – Services and Products	$	45,211		$	14,910		—			—		$	60,121

Operating costs and expenses:
Cost of revenues		24,703			7,700		—			—			32,403
Research and development		281			1,225	$	46			—			1,552
Selling, general and administrative		12,523			5,038		33		$	3,433			21,027
Legal and related expenses		96			6		—			2,830			2,932
Total operating costs and expenses		37,603			13,969		79			6,263			57,914

Operating income (loss)		7,608			941		(79	)		(6,263	)		2,207

Other income (expense):
Interest		(10	)		18		—			(108	)		(100	)
Other		29			4		—			—			33
Foreign exchange gain					461		—			—			461
Net income (loss)	$	7,627		$	1,424	$	(79	)	$	(6,371	)	$	2,601

Depreciation and amortization included above	$	790		$	373	$	—		$	132		$	1,295

Share-based compensation included in above:
Selling, general and administrative		19			32		—			265			316
Cost of revenues		27			—		—			—			27
Total	$	46		$	32	$	—		$	265		$	343

Capital expenditures	$	881		$	198	$	—		$	44		$	1,123